Madrigal Pharmaceuticals Inc. Common Stock (MDGL)
Stock · NASDAQ · Health Care
$449.34as of 10/16/2026
Price chart
Active signals
Resistance level
$508.58
Industry
Biotechnology: Pharmaceutical Preparations
MDGL Signal Track Record
How signals performed across all stocks →What MDGL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +1.5% | 53% | September 8, 2026 |
| Bollinger Band Breakdown | 22 | -2.0% | 45% | October 8, 2026 |
| Bollinger Band Breakout | 23 | -0.4% | 43% | July 8, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +5.5% | 64% | September 23, 2026 |
| Any 20-session window (baseline) | -0.9% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MDGL
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 915
- Website
- www.madrigalpharma.com/
Fundamentals
- 1-day range
- $456.22$468.72
- Market cap
- $11.79B
- P/E (trailing)
- —
- P/E (forward)
- 47.77
- EPS (trailing)
- $-12.87
- Dividend yield
- —
- Beta
- -1.08
- Avg. volume
- 294.9K
- Dividend pay date
- July 25, 2016
52-week range
$393.61$615
Next earnings: November 4, 2026 · EPS estimate $-1.09Before Openconfirmed
Forecasts
18 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$962
+114.1%
Median
$661.5
+47.2%
Low
$543
+20.8%
Madrigal Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MDGLMadrigal Pharmaceuticals Inc. Common Stock$449.74▼ 2.19%Market cap $11.79BP/E —$393.61$615
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals Inc. Common Stock | $11.79B | — | $449.74 | ▼ 2.19% | $393.61$615 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In FocusYahoo · 10/8/2026
- Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year RunYahoo · 10/8/2026
- Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?Yahoo · 10/7/2026
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Yahoo · 10/7/2026
- Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffrabenzinga · 10/6/2026
- Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsYahoo · 10/6/2026
- Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To RezdiffraBenzinga · 10/6/2026
- Novo Nordisk: Capital Markets Day Reveals Its Next Growth EngineSeekingAlpha · 9/24/2026
- Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price TargetBenzinga · 9/24/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
7.0K
- William John Sibold · September 11, 2026 · Sale120 @ $546.38
- William John Sibold · September 11, 2026 · Sale761 @ $544.83
- William John Sibold · September 11, 2026 · Sale1.5K @ $544.02
- William John Sibold · September 11, 2026 · Sale1.2K @ $542.6
- William John Sibold · September 11, 2026 · Sale687 @ $540.59
- William John Sibold · September 11, 2026 · Sale160 @ $537.62
- William John Sibold · September 11, 2026 · Sale218 @ $535.94
- William John Sibold · September 11, 2026 · Sale106 @ $534.06
- William John Sibold · September 11, 2026 · Sale60 @ $533.09
- William John Sibold · September 11, 2026 · Sale368 @ $541.64
- William John Sibold · September 9, 2026 · Sale160 @ $542.55
- William John Sibold · September 9, 2026 · Sale362 @ $541.65
- William John Sibold · September 9, 2026 · Sale505 @ $540.19
- William John Sibold · September 9, 2026 · Sale215 @ $539.03
- William John Sibold · September 9, 2026 · Sale520 @ $538.3
Institutional Ownership
March 31, 2026
- Total shares held
- 23.72M
- Total value held
- $12.09B
- Institutional holders
- 375
Top holders this quarter
- Unknown2.14M
- Unknown2.02M
- Unknown1.99M
- Unknown1.82M
- Unknown1.56M
- Unknown1.39M
- Unknown827.1K
- Unknown695.0K
- Unknown609.5K
- Unknown602.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data
Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.